Thermo-chemo-radiotherapy of esophageal cancer. A preliminary report of 34 cases

Hou, Bing-Sen; Xiong, Qun-Bin; Li, Ding-Jiu

doi:10.1002/1097-0142(19891101)64:9<1777::aid-cncr2820640903>3.0.co;2-i

Cited by 30 publications

(9 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A few examples of trimodality studies are given in table 3 (Hou et al 1989, Ueo and Sugimachi 1990, Bornstein et al 1992, Sugimachi et al 1992, Amichetti et al 1993, Ohno et al 1997, Rau et al 1998.…”

Section: Hyperthermia and Radiochemotherapymentioning

confidence: 99%

“…There, application of hyperthermia by using intracavitary microwave or radiofrequency (RF) heating devices in combination with chemotherapy and/or radiation therapy has been investigated for a long time, and current phase II/III trials are ongoing. In an early report from a cooperative group from Henan in China, Hou et al (1989) reported on pre-operative treatment of 23 cases of esophageal cancer by triple therapy (table 3). Their previous results (Li and Hou 1987) using intraluminal microwave hyperthermia and chemotherapy alone showed an overall response rate of 65% (8 CR/13 PR) in 32 cases (table 2).…”

Section: Hyperthermia and Radiochemotherapymentioning

confidence: 99%

“…But, only two patients with CR survived more than 2 years without any evidence of disease. By the addition of radiation to thermochemotherapy (`triple modality' ), total response rate was 94% and 2-year survival 48% (Hou et al 1989).…”

Section: Hyperthermia and Radiochemotherapymentioning

confidence: 99%

See 2 more Smart Citations

Hyperthermia in oncology

Falk¹,

Issels²

2001

Int. J. Hyperthermia

545

291

View full text Add to dashboard Cite

The purpose of this article is to provide an overview on the current clinical application of hyperthermia combined with conventional treatment modalities (e.g. ionizing radiation, chemotherapy) in the treatment of malignant disease. The clinical application of hyperthermia with increase of tissue temperatures (range 40-44 degrees C) has been integrated in multimodal anti-cancer strategies. This review describes selected phase I or II (n = 17) and phase III trials (n = 16) investigating the effect of hyperthermia combined with radiotherapy (n = 10 trials), chemotherapy (n = 15 trials), or both (n = 8 trials) in a total of more than 2200 patients. The trials were performed in a variety of solid tumours (e.g. melanoma, head and neck cancer, breast cancer, cancer of the gastrointestinal or urogenital tract, glioblastoma, sarcoma) in paediatric or adult patients. Profound research has produced a scientific basis for the simultaneous application of hyperthermia in combination with ionizing radiation and/or systemic chemotherapy. Hyperthermia is becoming more accepted clinically, due to the substantial technical improvements made in achieving selected increase of temperatures in superficial and deep-seated tumours. At present, the combination of hyperthermia and chemotherapy or radiochemotherapy is further tested within clinical protocols (phase II/III) in order to improve local tumour control and relapse-free survival in patients with high-risk or advanced tumours of different entities.

show abstract

Section: Hyperthermia and Radiochemotherapymentioning

confidence: 99%

Section: Hyperthermia and Radiochemotherapymentioning

confidence: 99%

See 1 more Smart Citation

Hyperthermia in oncology

Falk¹,

Issels²

2001

Int. J. Hyperthermia

545

291

View full text Add to dashboard Cite

show abstract

“…Clinical studies with the combination of local, intraluminal hyperthermia combined with CDDP (Li & Hou, 1987) or with CDDP plus radiation (Hou et al, 1989) for the treatment of oesophageal cancer showed promising…”

Section: And In Vivo In Fsaiic Fibrosarcomamentioning

confidence: 99%

Modulation of cis-diamminedichloroplatinum(II) resistance: a review

Timmer‐Bosscha

Mulder²,

Vries³

1992

Br J Cancer

148

View full text Add to dashboard Cite

Summary In this review an inventory is made of agents used to circumvent cis-diamminedichloroplatinum(II) (CDDP) resistance in vitro and in vivo. Agents that affect CDDP accumulation and membrane related systems, cytoplasmic defense mechanisms, as well as DNA accessibility and repair are reviewed.In resistant cell lines that have decreased accumulation, this can be restored by hyperthermic treatment. With or without effects on accumulation compounds that affect cell signal transduction often increase CDDP cytotoxicity. Calcium channel blockers and calmodulin inhibitors do not seem to be uniformly good modulators of CDDP resistance. For transduction modulators as well as cellular calcium affecting agents mechanisms are mainly unclear or controversial. Glutathione appears, with the now available agents, to be the most promising target for modulation of cytoplasmic defense mechanisms. At the nuclear level the inhibition of DNA repair related enzymes as well as the use of modified nucleosides to interfere with repair is studied in various cell lines. Results with these agents suggest opportunities for clinically feasible cytotoxicity modulation. DNA accessibility could in vitro be affected, but seems to be an unreliable target for modulation. Whenever possible the resistance mechanism affected and the mode of action of the modulator are discussed. As an alternative for modulation another method of overcoming CDDP resistance namely the application of CDDP analogues is considered.

show abstract

“…A few papers on the intra-cavitary hyperthermia combined with radiation and chemotherapy in the treatment of esophageal cancer have been reported (Sugimachi and Inokuchi 1986, Li and Hou 1987, Hou et al 1989, Sugimachi et al 1992), but the thermal dosimetry during the intra-cavitary heating has not yet been described in detail. The Duke' s thermal dosimetry system has been developed (Leopold et al 1992, Dewhirst 1993, Oleson 1995, which has been proved as a good indicator for tumour control by several reports (Sneed et al 1992.…”

Section: Introductionmentioning

confidence: 99%

Thermometric analysis of intra-cavitary hyperthermia for esophageal cancer

Qi¹

1999

International Journal of Hyperthermia

View full text Add to dashboard Cite

Thermometric analysis was carried out in 51 patients with esophageal cancer treated with intra-cavitary hyperthermia combined with radio chemotherapy, to test whether temperature index (T20, T50) and T90) could be used as an indicator for tumour control. Hyperthermia was administered by intra-cavitary microwave applicator. The T20, T50 and T90 were deducted from the temperature sensors T0 and T3 situated at the center of the tumour surface and 3cm from it. Eighteen patients with local control > or =36 months were named long term control patients (LC), 24 patients with local recurrence within 24 months (LR) (there were no events occurring between 24 and 36 months) and nine patients died of metastasis without local recurrence (DM). The overall survival rates were 80.4 +/- 5.6% at 1 year, 38.3 +/- 6.9% at 3 years and 31 +/- 6.7% at 5 years, respectively. Chi-square test showed no influence of the number of hyperthermia sessions on the local control (p > 0.25). The 5-year local control rate was 18.8% for the patients with T90 < 43 degrees C and 45% for those with T90 > or = 43 degrees C (p < 0.01). The average T90 was 43.76 +/- 0.74 degrees C for the LC patients and 43.17 +/- 0.57 degrees C for those LR (p = 0.024). The mean T90 was higher than 43 degrees C in 94.4% of LC, whereas in 58.8% of LR. The study suggested that T90 was a good parameter for thermal dose in the intracavitary hyperthermia for the treatment of esophageal cancer.

show abstract

Thermo-chemo-radiotherapy of esophageal cancer. A preliminary report of 34 cases

Cited by 30 publications

References 5 publications

Hyperthermia in oncology

Hyperthermia in oncology

Modulation of cis-diamminedichloroplatinum(II) resistance: a review

Thermometric analysis of intra-cavitary hyperthermia for esophageal cancer

Contact Info

Product

Resources

About